약물전달용 나노입자 시장 예측(-2032년) : 유형별, 재료별, 투여 경로별, 용도별, 최종 사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Nanoparticles for Drug Delivery Market is accounted for $105.7 million in 2025 and is expected to reach $180.1 million by 2032 growing at a CAGR of 7.9% during the forecast period. Nanoparticles for drug delivery are ultra-small carriers designed to transport therapeutic agents directly to targeted cells or tissues. These particles enhance drug solubility, stability, and bioavailability while minimizing side effects. They can be engineered from lipids, polymers, metals, or proteins and are used in treating cancer, infections, and chronic diseases. Nanoparticles enable controlled release, crossing biological barriers, and precision targeting. Their size and surface properties are tailored to optimize interaction with biological systems for effective treatment.

According to NIH, nanoparticles enable targeted drug delivery by crossing biological barriers, improving bioavailability, and minimizing side effects in cancer and chronic disease therapies.

Market Dynamics:

Driver:

Rising chronic and cancer cases

The growing prevalence of chronic diseases, including cardiovascular disorders, diabetes, and especially cancer, is fueling demand for nanoparticle-based drug delivery systems. These platforms improve bioavailability, target precision, and reduce side effects, making them ideal for managing long-term illnesses. With cancer cases surging globally, nanoparticles are increasingly deployed in chemotherapy and targeted treatments. This medical necessity drives innovation and adoption, positioning nanoparticles as a critical enabler in advancing modern therapeutics across oncology, metabolic diseases, and neurological conditions.

Restraint:

Regulatory complexities for nano products

Stringent regulatory frameworks act as a major restraint for the nanoparticle drug delivery market. Nanomedicines often face lengthy approval timelines due to complex safety, toxicity, and efficacy evaluations required by agencies like the FDA and EMA. The absence of universally harmonized guidelines further complicates global commercialization. These challenges increase R&D costs and delay product launches, deterring smaller companies from market entry. Consequently, regulatory complexities hinder rapid adoption, despite strong clinical demand for innovative nanoparticle-based delivery platforms across therapeutic segments.

Opportunity:

Nanoparticle vaccines and gene therapy

Advancements in nanoparticle-enabled vaccines and gene therapy present immense opportunities for this market. Nanocarriers enhance stability, targeted delivery, and cellular uptake of genetic material, significantly improving treatment outcomes. Their use in mRNA COVID-19 vaccines showcased the potential of lipid nanoparticles, setting a precedent for broader applications in infectious diseases and rare genetic disorders. Growing investment in personalized medicine and advanced biologics further expands these opportunities, positioning nanoparticles as pivotal tools in next-generation therapies with high clinical and commercial promise.

Threat:

Competition from alternative technologies

Competition from alternative drug delivery technologies poses a threat to market expansion. Platforms like monoclonal antibodies, viral vectors, and advanced polymer therapeutics are also achieving targeted delivery with proven efficacy. These established modalities often benefit from clearer regulatory pathways and clinician familiarity. If nanoparticles fail to demonstrate superior safety, cost-effectiveness, and scalability, they risk losing adoption share. Consequently, the presence of competing platforms challenges market growth, compelling nanoparticle innovators to continuously differentiate through innovation and therapeutic performance.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated nanoparticle drug delivery adoption, especially through lipid nanoparticles in mRNA vaccines. This global success story highlighted the scalability and efficacy of nanocarriers in rapid vaccine development. Increased R&D funding and government support propelled broader applications in immunology, oncology, and infectious diseases. While early supply chain disruptions hampered clinical trials, post-pandemic investments in nanomedicine surged. Overall, COVID-19 positioned nanoparticles as indispensable tools in modern healthcare, catalyzing trust, innovation, and future pipeline expansion for drug delivery platforms.

The liposomes segment is expected to be the largest during the forecast period

The liposomes segment is projected to dominate the market during the forecast period, owing to their established safety profile, biocompatibility, and ability to encapsulate both hydrophilic and hydrophobic drugs. Liposomes improve targeted delivery, reduce systemic toxicity, and enhance drug solubility, making them widely used in cancer therapy, antifungal treatments, and vaccines. Strong clinical adoption and FDA approvals reinforce their market position. The success of liposomal formulations like Doxil highlights their therapeutic relevance, ensuring continued dominance within nanoparticle-based drug delivery.

The polymer-based segment is expected to have the highest CAGR during the forecast period

The polymer-based nanoparticles segment is forecasted to witness the highest CAGR, impelled by advancements in biodegradable polymers and their versatility in drug delivery. These carriers enable controlled release, prolonged circulation time, and precise targeting, making them valuable in cancer, gene therapy, and neurological disorders. Rapid innovation in polymer chemistry supports safer and more effective formulations. Increasing R&D investments and collaborations between pharmaceutical firms and research institutions are fueling growth, positioning polymer-based nanoparticles as a rapidly expanding frontier in nanomedicine.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising healthcare investments, growing cancer prevalence, and expansion of pharmaceutical manufacturing hubs. Countries such as China, India, and Japan are investing heavily in nanotechnology research and clinical applications. Favorable government initiatives, cost-effective production capabilities, and rising demand for advanced therapies further boost adoption. Additionally, collaborations between academic institutions and pharmaceutical companies accelerate clinical trials, making Asia Pacific a leading region in nanoparticle drug delivery adoption.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to strong R&D capabilities, advanced healthcare infrastructure, and early adoption of innovative therapies. The U.S. is at the forefront with numerous FDA-approved nanoparticle-based drugs and vaccines, supported by significant investments from biotech firms and government agencies. Favorable reimbursement frameworks, rising incidence of chronic diseases, and robust clinical trial pipelines further accelerate growth. North America's leadership in nanomedicine innovation ensures its position as the fastest-growing regional market.

Key players in the market

Some of the key players in Nanoparticles for Drug Delivery Market include Merck & Co., Pfizer, Johnson & Johnson, Novartis, Roche, AbbVie, Sanofi, Amgen, Celgene, Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb, Biogen, Eli Lilly, Regeneron Pharmaceuticals, Medtronic, and MedImmune.

Key Developments:

In August 2025, Merck & Co. launched a lipid nanoparticle platform for oncology mRNA delivery, optimizing tumor targeting while minimizing systemic toxicity. This innovation advances precision cancer therapeutics, improving safety and treatment outcomes.

In July 2025, Pfizer introduced a polymeric nanoparticle intranasal vaccine formulation, designed to strengthen mucosal immunity. By simplifying administration and logistics, it supports large-scale immunization programs with improved efficacy and patient accessibility.

In June 2025, Johnson & Johnson unveiled a dual-layer nanoparticle system for autoimmune therapies, enabling sequential release of immunomodulators. This controlled delivery approach enhances therapeutic efficacy, reduces side effects, and supports long-term immune regulation.

Types Covered:

• Liposomes
• Niosomes
• Micelles
• Solid Lipid Nanoparticles
• Nanoemulsions
• Polymeric Nanoparticles

Materials Covered:

• Lipid-Based
• Polymer-Based
• Metallic
• Quantum Dots
• Dendrimers
• Carbon-Based

Route of Administrations Covered:

• Oral
• Intravenous
• Topical
• Pulmonary
• Nasal
• Ocular
• Transdermal

Applications Covered:

• Cancer Therapy
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Vaccines

End Users Covered:

• Hospitals
• Pharmaceutical Companies
• Research Laboratories
• Biotechnology Firms

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Nanoparticles for Drug Delivery Market, By Type

• 5.1 Introduction
• 5.2 Liposomes
• 5.3 Niosomes
• 5.4 Micelles
• 5.5 Solid Lipid Nanoparticles
• 5.6 Nanoemulsions
• 5.7 Polymeric Nanoparticles

6 Global Nanoparticles for Drug Delivery Market, By Material

• 6.1 Introduction
• 6.2 Lipid-Based
• 6.3 Polymer-Based
• 6.4 Metallic
• 6.5 Quantum Dots
• 6.6 Dendrimers
• 6.7 Carbon-Based

7 Global Nanoparticles for Drug Delivery Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Intravenous
• 7.4 Topical
• 7.5 Pulmonary
• 7.6 Nasal
• 7.7 Ocular
• 7.8 Transdermal

8 Global Nanoparticles for Drug Delivery Market, By Application

• 8.1 Introduction
• 8.2 Cancer Therapy
• 8.3 Cardiovascular Diseases
• 8.4 Neurological Disorders
• 8.5 Infectious Diseases
• 8.6 Vaccines

9 Global Nanoparticles for Drug Delivery Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Pharmaceutical Companies
• 9.4 Research Laboratories
• 9.5 Biotechnology Firms

10 Global Nanoparticles for Drug Delivery Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Merck & Co.
• 12.2 Pfizer
• 12.3 Johnson & Johnson
• 12.4 Novartis
• 12.5 Roche
• 12.6 AbbVie
• 12.7 Sanofi
• 12.8 Amgen
• 12.9 Celgene
• 12.10 Gilead Sciences
• 12.11 GlaxoSmithKline
• 12.12 Bristol-Myers Squibb
• 12.13 Biogen
• 12.14 Eli Lilly
• 12.15 Regeneron Pharmaceuticals
• 12.16 Medtronic
• 12.17 MedImmune